On Thursday, U.K. lawmakers just greenlit a drug from pharmaceutical giant GlaxoSmithKline (GSK) that is said to treat individuals who are deemed to have higher risks of catching Covid-19. The pharma firm even claims that the latest medication may well seem to be effective against the recently identified Omicron strain.
Dubbed as sotrovimab, the new drug – according to the Medicines and Healthcare products Regulatory Agency (MHRA) – is an antibody treatment that is said to be safe and effective in the reduction of the risk of getting hospitalized and death in individuals having mild to moderate symptoms of Covid-19 who are at an elevated risk of progressing to a severe one, Medical Xpress reports.
Further, this new drug is a monoclonal antibody which is a type of protein that binds itself to the coronavirus’ spike protein. This results in the reduction of the virus’ activity to access the body cells.
Alongside GSK, California-based Vir Biotechnology also took part in the development of sotrovimab.
Sotrovimab against the Omicron variant
In a statement by GSK, it was revealed within the drug’s preclinical data that it is retaining the activity against key mutations of the latest Omicron strain of the coronavirus.
Additionally, the World Health Organization (WHO) stated that sotrovimab has shown continuous activity against the entirety of the tested variants of interest and concern.
It was highlighted that there is still continuous testing to confirm sotrovimab’s neutralizing activity against all of the mutations of the Omicron variant as an update is scheduled to be rolled out by the end of the year.
MHRA revealed that a dose of this new drug from GSK can reduce the risk of hospitalization and death by 79 percent among adults with symptomatic Covid-19 infection.
Omicron case in the U.S.
Chronicle News recently reported that Covid-19’s new Omicron variant has already entered the United States as this was detected from an individual in California who happens to have traveled from South Africa. According to National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci, the person is undergoing self-quarantine and is as of late experiencing mild symptoms as these are said to be improving.